Form 4: Eli Lilly Executive Johna Norton Reports Stock Transactions

Executive Vice President of Global Quality at Eli Lilly, Johna Norton, reported the acquisition of 1,668 shares of common stock and 1,308 restricted stock units, along with the disposal of 402 shares.

Summary

• Johna Norton, an Executive Vice President at Eli Lilly, filed a Form 4 detailing changes in her beneficial ownership of company stock.
• On February 12, 2024, Ms. Norton acquired 1,668 shares of Eli Lilly common stock at a price of $737.26 per share.
• She also acquired 1,308 restricted stock units, each representing a contingent right to receive one share of common stock, exercisable on February 1, 2025.
• Additionally, Ms. Norton disposed of 402 shares of common stock held indirectly through a 401(k) plan.
• She also has indirect ownership of 1,769 shares and 128 shares through a 401(k) plan and a partner respectively.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it is a routine filing of stock transactions by an executive. There are no significant positive or negative implications.

Positives

• The acquisition of 1,668 shares by an executive may signal confidence in the company's future performance.
• The grant of 1,308 restricted stock units aligns the executive's interests with the long-term success of the company.

Negatives

• The disposal of 402 shares, while indirect, could be interpreted as a slight reduction in the executive's overall stake.

Risks

• Changes in executive stock ownership can sometimes be perceived negatively by the market, although this is a routine filing.
• The vesting of restricted stock units in the future could potentially lead to further stock sales by the executive.

Future Outlook

The restricted stock units will vest on February 1, 2025, potentially leading to an increase in the number of shares held by the executive.

Industry Context

This is a standard SEC Form 4 filing, which is common for executives of publicly traded companies. It provides transparency into the stock transactions of company insiders.

Comparison to Industry Standards

• Executive stock transactions are a common practice across publicly traded companies, and this filing is consistent with standard reporting requirements.
• Other pharmaceutical companies such as Pfizer (PFE) and Merck (MRK) also have executives who regularly report stock transactions via SEC Form 4 filings.
• The acquisition of stock and restricted stock units is a typical form of executive compensation in the pharmaceutical industry.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholder sentiment, but are generally considered routine.
• The vesting of restricted stock units could potentially increase the number of shares held by the executive in the future.

Key Dates

Keywords

Form 4, insider trading, stock acquisition, restricted stock units, executive compensation, beneficial ownership, Eli Lilly, LLY